PE20090999A1 - Nuevos derivados de metil-bencimidazol - Google Patents
Nuevos derivados de metil-bencimidazolInfo
- Publication number
- PE20090999A1 PE20090999A1 PE2008001917A PE2008001917A PE20090999A1 PE 20090999 A1 PE20090999 A1 PE 20090999A1 PE 2008001917 A PE2008001917 A PE 2008001917A PE 2008001917 A PE2008001917 A PE 2008001917A PE 20090999 A1 PE20090999 A1 PE 20090999A1
- Authority
- PE
- Peru
- Prior art keywords
- cycloalkyl
- alkyl
- difluor
- benzoimidazol
- acetamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE METIL-BENCIMIDAZOL DE FORMULA (I) DONDE R1 ES CICLOALQUILO(C3-C10), ALQUILO(C1-C7) INFERIOR, ARILO, ENTRE OTROS; R2 ES H O ALQUILO(C1-C7) INFERIOR; R3 ES CICLOALQUILO(C3-C10), ALQUILO(C1-C7) INFERIOR, CICLOALQUIL(C3-C10)-ALQUILO(C1-C7) INFERIOR, ENTRE OTROS; R4 ES ARILO, CICLOALQUILO(C3-C10), HETEROARILO, ENTRE OTROS; R5 Y R6 SON CADA UNO H, HIDROXI, ALCOXI(C1-C7) INFERIOR, ENTRE OTROS; R7, R8, R9 Y R10 SON CADA UNO H, HALOGENO, HIDROXI, ALQUILO(C1-C7) INFERIOR, ALCOXI(C1-C7) INFERIOR, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[2-(3-CLORO-BENCIL)-5,6-DIFLUOR-BENZOIMIDAZOL-1-IL]-2,N-DICICLOHEXIL-ACETAMIDA, 2,N-DICICLOHEXIL-2-[5,6-DIFLUOR-2-(4-ISOPROPIL-BENCIL)-BENZOIMIDAZOL-1-IL]-ACETAMIDA, 2,N-DICICLOHEXIL-2-[2-(4-ETOXI-BENCIL)-5,6-DIFLUOR-BENZOIMIDAZOL-1-IL]-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR X DE FARNESOIDE (FXR) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDAD ATEROSCLEROTICA, DIABETES MELLITUS, SINDROME METABOLICO, OBESIDAD
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07120737 | 2007-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090999A1 true PE20090999A1 (es) | 2009-07-20 |
Family
ID=40551982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001917A PE20090999A1 (es) | 2007-11-15 | 2008-11-12 | Nuevos derivados de metil-bencimidazol |
Country Status (16)
Country | Link |
---|---|
US (2) | US7825258B2 (es) |
EP (1) | EP2222645B1 (es) |
JP (1) | JP5222953B2 (es) |
KR (1) | KR101176721B1 (es) |
CN (1) | CN101855214B (es) |
AR (1) | AR069306A1 (es) |
AU (1) | AU2008323017B2 (es) |
BR (1) | BRPI0818813A2 (es) |
CA (1) | CA2704074A1 (es) |
CL (1) | CL2008003372A1 (es) |
ES (1) | ES2403592T3 (es) |
IL (1) | IL205207A0 (es) |
MX (1) | MX2010005164A (es) |
PE (1) | PE20090999A1 (es) |
TW (1) | TW200924755A (es) |
WO (1) | WO2009062874A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5530445B2 (ja) * | 2008-09-11 | 2014-06-25 | エフ.ホフマン−ラ ロシュ アーゲー | 新規ベンゾイミダゾール誘導体 |
ES2444791T3 (es) * | 2008-10-15 | 2014-02-26 | F. Hoffmann-La Roche Ag | Nuevos derivados de benzimidazol |
US8309581B2 (en) * | 2009-09-29 | 2012-11-13 | Hoffmann-La Roche Inc. | Benzimidazole derivatives |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
BR122016011808B1 (pt) * | 2012-06-19 | 2021-09-21 | Intercept Pharmaceuticals, Inc | Processos para preparar a forma 1 de ácido obeticólico e o ácido obeticólico cristalino |
KR101949251B1 (ko) | 2013-09-11 | 2019-02-18 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | B형간염바이러스 감염의 치료 방법 및 치료용 약학적 조성물 |
SG11201906987RA (en) | 2017-02-21 | 2019-09-27 | Genfit | Combination of a ppar agonist with a fxr agonist |
WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
WO2021188690A1 (en) * | 2020-03-18 | 2021-09-23 | Metacrine, Inc. | Farnesoid x receptor agonists for the treatment of disease |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000004900A1 (en) * | 1998-07-20 | 2000-02-03 | Bristol-Myers Squibb Company | Substituted benzimidazole antiviral agents |
SG159380A1 (en) | 2002-02-06 | 2010-03-30 | Vertex Pharma | Heteroaryl compounds useful as inhibitors of gsk-3 |
CN1816530A (zh) * | 2003-07-01 | 2006-08-09 | 麦克公司 | 用于治疗高眼压症的眼用组合物 |
KR101237623B1 (ko) * | 2006-06-29 | 2013-02-26 | 에프. 호프만-라 로슈 아게 | 벤즈이미다졸 유도체, 이의 제조방법, fxr 작용물질로서이의 용도, 및 이를 함유하는 약학 제제 |
KR101237577B1 (ko) * | 2007-08-27 | 2013-02-26 | 에프. 호프만-라 로슈 아게 | Fxr 작용제로서 사용되는 벤즈이미다졸 유도체 |
-
2008
- 2008-11-05 WO PCT/EP2008/065012 patent/WO2009062874A2/en active Application Filing
- 2008-11-05 MX MX2010005164A patent/MX2010005164A/es active IP Right Grant
- 2008-11-05 CA CA2704074A patent/CA2704074A1/en not_active Abandoned
- 2008-11-05 EP EP08849394A patent/EP2222645B1/en not_active Not-in-force
- 2008-11-05 KR KR1020107010507A patent/KR101176721B1/ko not_active IP Right Cessation
- 2008-11-05 AU AU2008323017A patent/AU2008323017B2/en not_active Expired - Fee Related
- 2008-11-05 CN CN2008801158570A patent/CN101855214B/zh not_active Expired - Fee Related
- 2008-11-05 US US12/265,049 patent/US7825258B2/en not_active Expired - Fee Related
- 2008-11-05 ES ES08849394T patent/ES2403592T3/es active Active
- 2008-11-05 JP JP2010533538A patent/JP5222953B2/ja not_active Expired - Fee Related
- 2008-11-05 BR BRPI0818813 patent/BRPI0818813A2/pt not_active IP Right Cessation
- 2008-11-12 PE PE2008001917A patent/PE20090999A1/es not_active Application Discontinuation
- 2008-11-13 AR ARP080104952A patent/AR069306A1/es unknown
- 2008-11-13 CL CL2008003372A patent/CL2008003372A1/es unknown
- 2008-11-14 TW TW097144263A patent/TW200924755A/zh unknown
-
2010
- 2010-04-19 IL IL205207A patent/IL205207A0/en unknown
- 2010-08-25 US US12/862,823 patent/US8008503B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2704074A1 (en) | 2009-05-22 |
TW200924755A (en) | 2009-06-16 |
JP5222953B2 (ja) | 2013-06-26 |
CN101855214B (zh) | 2012-12-26 |
US20100331371A1 (en) | 2010-12-30 |
CN101855214A (zh) | 2010-10-06 |
JP2011503136A (ja) | 2011-01-27 |
KR101176721B1 (ko) | 2012-08-23 |
AR069306A1 (es) | 2010-01-13 |
KR20100071102A (ko) | 2010-06-28 |
IL205207A0 (en) | 2010-12-30 |
EP2222645A2 (en) | 2010-09-01 |
AU2008323017A1 (en) | 2009-05-22 |
AU2008323017B2 (en) | 2012-12-20 |
CL2008003372A1 (es) | 2010-01-04 |
US8008503B2 (en) | 2011-08-30 |
US7825258B2 (en) | 2010-11-02 |
MX2010005164A (es) | 2010-05-27 |
BRPI0818813A2 (pt) | 2015-04-22 |
WO2009062874A3 (en) | 2009-07-09 |
ES2403592T3 (es) | 2013-05-20 |
WO2009062874A2 (en) | 2009-05-22 |
US20090131482A1 (en) | 2009-05-21 |
EP2222645B1 (en) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090999A1 (es) | Nuevos derivados de metil-bencimidazol | |
PE20090622A1 (es) | Nuevos derivados de bencimidazol sustituido | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20120790A1 (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 | |
PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
PE20080065A1 (es) | Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20070528A1 (es) | Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1 | |
PE20110684A1 (es) | Agonistas de los receptores de la melanocortina | |
PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
PE20090482A1 (es) | Derivados heterociclicos como antagonistas del receptor ccr2 | |
PE20121058A1 (es) | Compuestos que modulan el receptor de androgenos | |
PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20080697A1 (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion | |
PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
PE20080278A1 (es) | Compuestos de benzimidazolilo | |
PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
PE20081485A1 (es) | Derivados de sulfonamida | |
AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
PE20090741A1 (es) | Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano | |
PE20080676A1 (es) | Derivados de indol como antagonistas del receptor de glucagon | |
PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
PE20090592A1 (es) | Nuevos derivados de piperazina-amida | |
PE20080858A1 (es) | Compuestos de n-aril pirazol y composiciones que los contienen | |
PE20071152A1 (es) | Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |